Sanofi SA vs ProShares Ultra Semiconductors — how do they compare? Sanofi SA trades at $43.7 (market cap $104.30B), while ProShares Ultra Semiconductors trades at $91.95. The key difference: Sanofi SA pays a 5.55% dividend while ProShares Ultra Semiconductors pays none, and ProShares Ultra Semiconductors is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | USD | |
|---|---|---|
Market Cap | $104.30B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $52.34 | $113.53 |
52-Week Low | $41.33 | $40.97 |
Enterprise Value | $124.19B | — |
Dividend Yield | 5.55% | — |
Trailing returns across standard periods
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →